Journal of Affective Disorders
Volume 126, Issue 1 , Pages 39-45, October 2010

Electroconvulsive therapy-induced persistent retrograde amnesia: Could it be minimised by ketamine or other pharmacological approaches?

  • Emily M. Gregory-Roberts

      Affiliations

    • Brain and Mind Research Institute, University of Sydney, Australia
    • Corresponding Author InformationCorresponding author. Brain and Mind Research Institute, 100 Mallett St, Camperdown, NSW 2050, Australia. Tel.: +61 2 9351 0781; fax: +61 2 9351 0855.
  • ,
  • Sharon L. Naismith

      Affiliations

    • Brain and Mind Research Institute, University of Sydney, Australia
  • ,
  • Karen M. Cullen

      Affiliations

    • School of Medical Sciences, University of Sydney, Australia
  • ,
  • Ian B. Hickie

      Affiliations

    • Brain and Mind Research Institute, University of Sydney, Australia

Received 15 June 2009; received in revised form 28 November 2009; accepted 28 November 2009.

Abstract 

Background

Certain pharmacological agents administered during electroconvulsive therapy may have the potential to prevent persistent retrograde amnesia induced during electroconvulsive therapy. This review examines mechanisms for electroconvulsive therapy-induced retrograde amnesia, and evaluates the suitability of the anaesthetic ketamine for preventing this amnestic outcome.

Methods

A review of human studies, animal models and theoretical models in light of memory dysfunction following electroconvulsive therapy was conducted. MEDLINE was searched from 1950 to April 2009 using the MeSH terms “electroconvulsive therapy”, “memory”, “memory short term”, “memory disorders”, “excitatory amino acid antagonists”, and “ketamine”. PREMEDLINE was searched using the terms “electroconvulsive therapy”, “amnesia” and “ketamine”. Additional keyword and reference list searches were performed. No language, date constraints or article type constraints were used.

Results

Disruption of long term potentiation as a mechanism for electroconvulsive therapy-induced retrograde amnesia is well supported. Based on this putative mechanism, an N-methyl-D-aspartate receptor antagonist would appear suitable for preventing the retrograde amnesia. Available evidence in animals and humans supports the prediction that ketamine, an anaesthetic agent and N-methyl-D-aspartate receptor antagonist, could effectively prevent electroconvulsive therapy-induced persistent retrograde amnesia. Whilst there are concerns about the use of ketamine with electroconvulsive therapy, such as possible psychotomimetic effects, on balance this anaesthetic agent may improve or hasten clinical response to electroconvulsive therapy.

Conclusions

A clinical trial is warranted to determine if ketamine anaesthesia during electroconvulsive therapy can lessen persistent retrograde amnesia and improve therapeutic response. Electroconvulsive therapy with ketamine anaesthesia may provide effective antidepressant action with minimal side effects.

Keywords: Electroconvulsive therapy, Amnesia, retrograde, Receptors, N-methyl-D-aspartate, Excitatory amino acid antagonists, Ketamine

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0165-0327(09)00525-4

doi:10.1016/j.jad.2009.11.018

Journal of Affective Disorders
Volume 126, Issue 1 , Pages 39-45, October 2010